Amorphous solid dispersions of dasatinib and uses thereof
Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.
1. A method of treating a proliferative disorder in a patient in need thereof, the method comprising administering to the patient a pharmaceutical composition comprising an amorphous solid dispersion;
wherein the amorphous solid dispersion consists essentially of dasatinib, a methacrylic acid and ethyl acrylate copolymer that exhibits pH-dependent solubility, and optionally one or more functional components selected from the group consisting of antioxidants, wetting agents, and solubilizers;
wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 30:70 to 95:5 (dasatinib:copolymer); and
wherein the patient has elevated gastric pH.
2. The method of claim 1 , wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater.
3. The method of claim 1 , wherein the amorphous solid dispersion consists essentially of dasatinib and the copolymer.
4. The method of claim 3 , wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater.
5. The method of claim 1 , wherein the amorphous solid dispersion consists of dasatinib and the copolymer.
6. The method of claim 5 , wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater.
7. The method of claim 1 , wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 40:60 to 70:30 (dasatinib:copolymer).
8. The method of claim 1 , wherein the amorphous solid dispersion includes one or more functional components selected from the group consisting of antioxidants, wetting agents, and solubilizers.
9. The method of claim 1 , wherein the one or more functional components includes one or more antioxidants that are present in an amount of 0.001% to 2% by weight of the amorphous solid dispersion.
10. The method of claim 9 , wherein the one or more antioxidants includes acetylcysteine, ascorbyl palmitate, butylated hydroxyanisole (“BHA”), butylated hydroxytoluene (“BHT”), monothioglycerol, potassium nitrate, sodium ascorbate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium bisulfate, vitamin E or a derivative thereof, propyl gallate, ethylenediaminetetraacetic acid (“EDTA”) or a salt thereof, diethylenetriaminepentaacetic acid (“DTPA”), bismuth sodium triglycollamate, or a combination thereof.
11. The method of claim 10 , wherein the one or more antioxidants are present in an amount of 0.05% to 0.5% by weight of the amorphous solid dispersion.
12. The method of claim 9 , wherein the one or more antioxidants comprises butylated hydroxytoluene.
13. The method of claim 9 , wherein the one or more antioxidants comprises propyl gallate.
14. The method of claim 1 , wherein the pharmaceutical composition comprises the amorphous solid dispersion and one or more pharmaceutically acceptable additives.
15. The method of claim 1 , wherein the pharmaceutical composition is a solid dosage form suitable for oral administration.
16. The method of claim 1 , wherein the pharmaceutical composition is a gastric acid-insensitive composition.
17. A method of treating a proliferative disorder in a patient in need thereof and having elevated gastric pH, the method comprising:
(a) identifying a condition by which the patient's gastric pH is chronically elevated; and
(b) administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising an amorphous solid dispersion;
wherein the amorphous solid dispersion consists essentially of dasatinib, a methacrylic acid and ethyl acrylate copolymer that exhibits pH-dependent solubility, and optionally one or more functional components selected from the group consisting of antioxidants, wetting agents, and solubilizers;
wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 30:70 to 95:5 (dasatinib:copolymer); and
wherein the therapeutically effective amount comprises 20 mg to 140 mg dasatinib.
18. The method of claim 17 , wherein the condition is achlorhydria or hypochlorhydria.
19. The method of claim 17 , wherein the condition is infection by Helicobacter pylori.
20. The method of claim 17 , wherein the amorphous solid dispersion consists essentially of dasatinib and the copolymer.
21. The method of claim 17 , wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater.
22. The method of claim 17 , wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 40:60 to 70:30 (dasatinib:copolymer).
23. The method of claim 17 , wherein the amorphous solid dispersion includes one or more functional components selected from the group consisting of antioxidants, wetting agents, and solubilizers.
24. The method of claim 23 , wherein the one or more functional components includes one or more antioxidants that are present in an amount of 0.001% to 2% by weight of the amorphous solid dispersion.
25. The method of claim 24 , wherein the one or more antioxidants includes acetylcysteine, ascorbyl palmitate, butylated hydroxyanisole (“BHA”), butylated hydroxytoluene (“BHT”), monothioglycerol, potassium nitrate, sodium ascorbate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium bisulfate, vitamin E or a derivative thereof, propyl gallate, ethylenediaminetetraacetic acid (“EDTA”) or a salt thereof, diethylenetriaminepentaacetic acid (“DTPA”), bismuth sodium triglycollamate, or a combination thereof.
26. The method of claim 17 , wherein the pharmaceutical composition is a solid dosage form suitable for oral administration.
27. The method of claim 17 , wherein the pharmaceutical composition is a gastric acid-insensitive composition.
28. A method of treating a proliferative disorder in a patient in need thereof, the method comprising administering to the patient a pharmaceutical composition comprising an amorphous solid dispersion;
wherein the amorphous solid dispersion consists essentially of dasatinib, a methacrylic acid and ethyl acrylate copolymer that exhibits pH-dependent solubility, and optionally one or more functional components selected from the group consisting of antioxidants, wetting agents, and solubilizers;
wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 30:70 to 95:5 (dasatinib:copolymer); and
wherein the pharmaceutical composition is administered without regard to whether the patient has elevated gastric pH.
29. A method of delivering a therapeutically relevant exposure of dasatinib to a subject who has elevated gastric pH, the method comprising administering to the subject a pharmaceutical composition comprising an amorphous solid dispersion;
wherein the amorphous solid dispersion consists essentially of dasatinib, a methacrylic acid and ethyl acrylate copolymer that exhibits pH-dependent solubility, and optionally one or more functional components selected from the group consisting of antioxidants, wetting agents, and solubilizers; and
wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 30:70 to 95:5 (dasatinib:copolymer).
30. The method of claim 29 , wherein the subject is a human patient.